<DOC>
	<DOC>NCT01127321</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of MEDI-570 in adult subjects with moderately to severely active systemic lupus erythematosus (SLE).</brief_summary>
	<brief_title>A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus</brief_title>
	<detailed_description>This is a Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and tolerability of escalating single subcutaneous doses of MEDI-570 in adult subjects with moderately to severely active SLE.</detailed_description>
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>Meet or have met at least 4 of the 11 revised American College of Rheumatology (ACR) classification criteria for systemic lupus erythematosus (SLE) Score greater than or equal to (&gt;=) 6 points on the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI2K) at Screening Ability to complete the study period, including followup period through Day 169 Willingness to forego other forms of experimental treatment during the study. History of cancer except basal cell carcinoma treated with apparent success with curative therapy &gt;=1 year before randomization into the study Evidence of active or latent tuberculosis (TB) History of primary immunodeficiency Evidence of infection at any time with hepatitis B or C virus or human immunodeficiency virus (HIV)1 or HIV2, or active infection with hepatitis A, as determined by results of testing at Screening History of sepsis or serious, recurrent, chronic infection, current signs and symptoms of clinically significant chronic infection, or recent (within 6 months before Baseline visit) serious infection Any history or evidence of opportunistic infection within 6 months of Screening including severe cytomegalovirus (CMV) or herpetic infections (such as disseminated herpes, herpes encephalitis, ophthalmic herpes) Receipt of cyclophosphamide (intravenous or oral) within 6 months of Screening Have any absolute contraindications to skin punch biopsies, for example, a history of coagulation disorders.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Systemic lupus erythematosus</keyword>
	<keyword>SLE</keyword>
	<keyword>MEDI-570</keyword>
</DOC>